esarley

While still the gold standard in clinical research, randomized controlled trials can be costly, time-consuming, and limited in their scope. This case from Professor Ariel Stern explores the potential of an innovative new approach to clinical trials and cancer therapies – adaptive platform trials. Could this design offer a more flexible and efficient way forward for clinical trials as a whole?

Healthcare companies are lagging behind. Oftentimes, clinical trial research still uses old-school processes like physical protocol binders, paper diaries, and decade old-software. Furthermore, only 5% of the U.S. population participates in clinical research. Andrea Coravos (MBA ’17) believes the time is ripe for innovative technologies – from virtual trials and digital biomarkers to improved software tools – to improve clinical trial execution and encourage broader participation from the public.